The editorial desk
Published analysis coverage from TrendyVest.
A person in Boston took an injection in one eye and went home with a bottle of an old acne antibiotic. Thirteen hundred dogs are asleep on rugs across America, half of them on a pill and half on nothing, and none of their owners know which.
Read articleIt is imaging fiber, the kind made for medical endoscopy, carrying hundreds of parallel data channels instead of a picture. Elsewhere, engineers are putting glass under processors and taking it out of the middle of cables.
Read articleRecursive self-improvement could reshape AI research, corporate economics, and scientific discovery over the next 18 months. The decisive question is not how much work AI can generate—but how much verified progress it can deliver.
Read articleLily Caruso on the $638 billion promise: what the first quarter has to show at 4:05 on Thursday, why the guide already tells you roughly what OCI has to print, the customer that is half the backlog and is forecast to lose $14 billion this year, the $90-to-95 billion the company has to spend before it collects, the rating that is one notch above junk, a stock that ran 15 percent into the print — and rows on the next twelve and twenty-four months.
Read articleA TrendyVest featured investigation. Lily Caruso
Read article*A feature: the most-quoted statistic in biotech — AI-discovered molecules passing Phase 1 at nearly twice the historical rate — is true, and it's being used to sell a story it doesn't support. Lily Caruso walks the funnel: why machines are brilliant at the chemistry test and haven't touched the biology test, what 117 clinical assets across 63 companies actually show, the one drug that reached Phase 3, the failures the pitch decks skip, and where the desk puts its odds on the first approval.*
Read article*Episode 24: three numbers for a morning of pardons — $223, where Nvidia opened after one conference call converted a week of fear into a parade; ten percent,
Read articleA TrendyVest deep analysis: somewhere between the AI trade's trillion-dollar arithmetic and the meme casino sits the strangest market on earth — small-cap biotech, where a company is worth $2.9 billion on a Monday and either $6 billion or $600 million by some unannounced Friday, depending on what a locked database says about a protein.
Read article*A TrendyVest deep analysis: BlackBerry —
Read articleA tsunami of companies is about to bring AI home — off the cloud, inside the building, behind their own locked doors. Wall Street is still staring at five frontier labs and hasn't priced who sells the house. Our research stack keeps spitting out the same three names: a disgraced box-builder the index just threw away, a landlord the Street thinks is finished growing, and a fallen king quietly building for the peace. Two of them report this month. An investigation.
Read articleAmazon reports tonight, and everyone will ask whether it beats. Wrong question. Twenty-nine years ago, Amazon got the market to sign a permission slip excusing it from the one rule every other company lives by — and last night, the market started revoking that rule for everybody else. Tonight isn't a test of Amazon. It's a test of the signature.
Read article### Coca-Cola reports before the bell tomorrow, and if you own it the right way, the number barely matters. This is a deep dive for the investor who measures in decades, not quarters — and the single strange fact that explains why a company selling roughly the same amount of soda it sold years ago keeps making its owners richer.
Read articleEveryone entering the open-source AI aisle asks the same thing: which one is best? Six families, one taxonomy, several inconvenient truths, and the question that actually decides — asked ahead of Monday's landing. An analysis.
Read articleA TrendyVest Docket Storyline tracking who captures the economic value created b
Read articleA sourced TrendyVest investigation into OpenAI
Read articleIs gold still a reliable crisis hedge? Follow the evidence, conditions, invalida
Read articleWhere does the AI infrastructure buildout break first? Follow the evidence acros
Read articleIs the retail investor entering a better research era or a noisier one? Follow t
Read article